{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:05:57Z","timestamp":1791389157638,"version":"4.3.3"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["Finance Code 001"],"award-info":[{"award-number":["Finance Code 001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s10072-020-04828-1","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T21:02:47Z","timestamp":1602795767000},"page":"73-80","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Detection of MOG-IgG by cell-based assay: moving from discovery to clinical practice"],"prefix":"10.1007","volume":"42","author":[{"given":"Amanda","family":"Marchionatti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Woodhall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Joseph","family":"Waters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7695-6020","authenticated-orcid":false,"given":"Douglas Kazutoshi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"key":"4828_CR1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.autrev.2015.12.004","volume":"15","author":"S Ramanathan","year":"2016","unstructured":"Ramanathan S, Dale RC, Brilot F (2016) Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev 15:307\u2013324. https:\/\/doi.org\/10.1016\/j.autrev.2015.12.004","journal-title":"Autoimmun Rev"},{"key":"4828_CR2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.msard.2018.07.025","volume":"25","author":"R Narayan","year":"2018","unstructured":"Narayan R, Simpson A, Fritsche K, Salama S, Pardo S, Mealy M, Paul F, Levy M (2018) MOG antibody disease: a review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 25:66\u201372. https:\/\/doi.org\/10.1016\/j.msard.2018.07.025","journal-title":"Mult Scler Relat Disord"},{"key":"4828_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2055217318796684","volume":"4","author":"S Asseyer","year":"2018","unstructured":"Asseyer S, Schmidt F, Chien C, Scheel M, Ruprecht K, Bellmann-Strobl J, Brandt AU, Paul F (2018) Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders. Mult Scler J Exp Transl Clin 4:1\u201312. https:\/\/doi.org\/10.1177\/2055217318796684","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"4828_CR4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12974-018-1108-6","volume":"15","author":"S Jarius","year":"2018","unstructured":"Jarius S, Ruprecht K, Stellmann JP, Huss A, Ayzenberg I, Willing A, Trebst C, Pawlitzki M, Abdelhak A, Gr\u00fcter T, Leypoldt F, Haas J, Kleiter I, Tumani H, Fechner K, Reindl M, Paul F, Wildemann B (2018) MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature. J Neuroinflammation 15:88. https:\/\/doi.org\/10.1186\/s12974-018-1108-6","journal-title":"J Neuroinflammation"},{"key":"4828_CR5","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/nm1488","volume":"13","author":"KC O\u2019Connor","year":"2007","unstructured":"O\u2019Connor KC, McLaughlin KA, De Jager PL, Chitnis T, Bettelli E, Xu C et al (2007) Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 13:211\u2013217. https:\/\/doi.org\/10.1038\/nm1488","journal-title":"Nat Med"},{"key":"4828_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2018.00217","volume":"9","author":"GR dos Passos","year":"2018","unstructured":"dos Passos GR, Oliveira LM, da Costa BK, Apostolos-Pereira SL, Callegaro D, Fujihara K, Sato DK (2018) MOG-IgG-associated optic neuritis, encephalitis, and myelitis: lessons learned from neuromyelitis optica spectrum disorder. Front Neurol 9:1\u201310. https:\/\/doi.org\/10.3389\/fneur.2018.00217","journal-title":"Front Neurol"},{"key":"4828_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1136\/jim-2019-001126","volume":"68","author":"JF Rosenthal","year":"2020","unstructured":"Rosenthal JF, Hoffman BM, Tyor WR (2020) CNS inflammatory demyelinating disorders: MS, NMOSD and MOG antibody associated disease. J Investig Med 68:321\u2013330. https:\/\/doi.org\/10.1136\/jim-2019-001126","journal-title":"J Investig Med"},{"key":"4828_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/NXI.0000000000000322","volume":"4","author":"R Ogawa","year":"2017","unstructured":"Ogawa R, Nakashima I, Takahashi T, Kaneko K, Akaishi T, Takai Y, Sato DK, Nishiyama S, Misu T, Kuroda H, Aoki M, Fujihara K (2017) MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol NeuroInflammation 4:1\u201310. https:\/\/doi.org\/10.1212\/NXI.0000000000000322","journal-title":"Neurol Neuroimmunol NeuroInflammation"},{"key":"4828_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jamaneurol.2017.3196","volume":"75","author":"SHM Hamid","year":"2018","unstructured":"Hamid SHM, Whittam D, Saviour M, Alorainy A, Mutch K, Linaker S, Solomon T, Bhojak M, Woodhall M, Waters P, Appleton R, Duddy M, Jacob A (2018) Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease. JAMA Neurol 75:65\u201371. https:\/\/doi.org\/10.1001\/jamaneurol.2017.3196","journal-title":"JAMA Neurol"},{"key":"4828_CR10","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1007\/s10072-020-04379-5","volume":"41","author":"G Musso","year":"2020","unstructured":"Musso G, Nosadini M, Gallo N, Sartori S, Seguso M, Plebani M (2020) Possible clinical role of MOG antibody testing in children presenting with acute neurological symptoms. Neurol Sci 41:2553\u20132559. https:\/\/doi.org\/10.1007\/s10072-020-04379-5","journal-title":"Neurol Sci"},{"key":"4828_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00115-018-0607-0","volume":"15","author":"S Jarius","year":"2018","unstructured":"Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, K\u00fcmpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B (2018) MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation 15:1\u201310. https:\/\/doi.org\/10.1007\/s00115-018-0607-0","journal-title":"J Neuroinflammation"},{"key":"4828_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","volume":"15","author":"M Reindl","year":"2019","unstructured":"Reindl M, Waters P (2019) Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol 15:89\u2013102. https:\/\/doi.org\/10.1038\/s41582-018-0112-x","journal-title":"Nat Rev Neurol"},{"key":"4828_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11940-019-0541-x","volume":"21","author":"Y Hacohen","year":"2019","unstructured":"Hacohen Y, Banwell B (2019) Treatment approaches for MOG-Ab-associated demyelination in children. Curr Treat Options Neurol 21:2. https:\/\/doi.org\/10.1007\/s11940-019-0541-x","journal-title":"Curr Treat Options Neurol"},{"key":"4828_CR14","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/cen3.12434","volume":"9","author":"K Fujihara","year":"2018","unstructured":"Fujihara K, Sato DK, Nakashima I, Takahashi T, Kaneko K, Ogawa R, Akaishi T, Matsumoto Y, Takai Y, Nishiyama S, Kuroda H, Misu T, Aoki M (2018) Myelin oligodendrocyte glycoprotein immunoglobulin G-associated disease: an overview. Clin Exp Neuroimmunol. 9:48\u201355. https:\/\/doi.org\/10.1111\/cen3.12434","journal-title":"Clin Exp Neuroimmunol."},{"key":"4828_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1471-4159.1999.0720001.x","volume":"72","author":"TG Johns","year":"1999","unstructured":"Johns TG, Bernard CCA (1999) The structure and function of myelin oligodendrocyte glycoprotein. J Neurochem 72:1\u20139. https:\/\/doi.org\/10.1046\/j.1471-4159.1999.0720001.x","journal-title":"J Neurochem"},{"key":"4828_CR16","doi-asserted-by":"publisher","first-page":"7990","DOI":"10.1073\/pnas.90.17.7990","volume":"90","author":"D Pham-Dinh","year":"1993","unstructured":"Pham-Dinh D, Mattei MG, Nussbaum JL, Roussel G, Pontarotti P, Roeckel N, Mather IH, Artzt K, Lindahl KF, Dautigny A (1993) Myelin\/oligodendrocyte glycoprotein is a member of a subset of the immunoglobulin superfamily encoded within the major histocompatibility complex. Proc Natl Acad Sci 90:7990\u20137994. https:\/\/doi.org\/10.1073\/pnas.90.17.7990","journal-title":"Proc Natl Acad Sci"},{"key":"4828_CR17","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/j.1471-4159.2006.04296.x","volume":"101","author":"C Allamargot","year":"2007","unstructured":"Allamargot C, Gardinier MV (2007) Alternative isoforms of myelin\/oligodendrocyte glycoprotein with variable cytoplasmic domains are expressed in human brain. J Neurochem 101:298\u2013312. https:\/\/doi.org\/10.1111\/j.1471-4159.2006.04296.x","journal-title":"J Neurochem"},{"key":"4828_CR18","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1111\/j.1471-4159.2007.04687.x","volume":"102","author":"LH Boyle","year":"2007","unstructured":"Boyle LH, Traherne JA, Plotnek G, Ward R, Trowsdale J (2007) Splice variation in the cytoplasmic domains of myelin oligodendrocyte glycoprotein affects its cellular localisation and transport. J Neurochem 102:1853\u20131862. https:\/\/doi.org\/10.1111\/j.1471-4159.2007.04687.x","journal-title":"J Neurochem"},{"key":"4828_CR19","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1046\/j.1432-1327.1998.2580478.x","volume":"258","author":"B della Gaspera","year":"1998","unstructured":"della Gaspera B, Pham-Dinh D, Roussel G, Nussbaum J-L, Dautigny A (1998) Membrane topology of the myelin\/oligodendrocyte glycoprotein. Eur J Biochem 258:478\u2013484. https:\/\/doi.org\/10.1046\/j.1432-1327.1998.2580478.x","journal-title":"Eur J Biochem"},{"key":"4828_CR20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/0165-5728(89)90014-3","volume":"22","author":"NJ Scolding","year":"1989","unstructured":"Scolding NJ, Frith S, Linington C, Morgan BP, Campbell AK, Compston DAS (1989) Myelin-oligodendrocyte glycoprotein (MOG) is a surface marker of oligodendrocyte maturation. J Neuroimmunol 22:169\u2013176. https:\/\/doi.org\/10.1016\/0165-5728(89)90014-3","journal-title":"J Neuroimmunol"},{"key":"4828_CR21","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1111\/j.1471-4159.1993.tb09822.x","volume":"61","author":"D Burger","year":"1993","unstructured":"Burger D, Steck AJ, Bernard CCA, de Rosbo NK (1993) Human myelin\/oligodendrocyte glycoprotein: a new member of the L2\/HNK-1 family. J Neurochem 61:1822\u20131827. https:\/\/doi.org\/10.1111\/j.1471-4159.1993.tb09822.x","journal-title":"J Neurochem"},{"key":"4828_CR22","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1046\/j.1471-4159.1994.62020777.x","volume":"62","author":"CA Dyer","year":"1994","unstructured":"Dyer CA, Matthieu J-M (1994) Antibodies to myelin\/oligodendrocyte-specific protein and myelin\/oligodendrocyte glycoprotein signal distinct changes in the Organization of Cultured Oligodendroglial Membrane Sheets. J Neurochem 62:777\u2013787. https:\/\/doi.org\/10.1046\/j.1471-4159.1994.62020777.x","journal-title":"J Neurochem"},{"key":"4828_CR23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0161-5890(97)00005-9","volume":"34","author":"TG Johns","year":"1997","unstructured":"Johns TG, Bernard CCA (1997) Binding of complement component Clq to myelin oligodendrocyte glycoprotein: a novel mechanism for regulating CNS inflammation. Mol Immunol 34:33\u201338. https:\/\/doi.org\/10.1016\/S0161-5890(97)00005-9","journal-title":"Mol Immunol"},{"key":"4828_CR24","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1083\/jcb.201504106","volume":"210","author":"HC von B\u00fcdingen","year":"2015","unstructured":"von B\u00fcdingen HC, Mei F, Greenfield A, Jahn S, Shen YAA, Reid HH, McKemy DD, Chan JR (2015) The myelin oligodendrocyte glycoprotein directly binds nerve growth factor to modulate central axon circuitry. J Cell Biol 210:891\u2013898. https:\/\/doi.org\/10.1083\/jcb.201504106","journal-title":"J Cell Biol"},{"key":"4828_CR25","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1093\/brain\/122.11.2047","volume":"122","author":"M Reindl","year":"1999","unstructured":"Reindl M, Linington C, Brehm U, Egg R, Dilitz E, Deisenhammer F, Poewe W, Berger T (1999) Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. Brain. 122:2047\u20132056. https:\/\/doi.org\/10.1093\/brain\/122.11.2047","journal-title":"Brain."},{"key":"4828_CR26","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1056\/NEJMoa022328","volume":"349","author":"T Berger","year":"2003","unstructured":"Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, Dilitz E, Deisenhammer F, Reindl M (2003) Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 349:139\u2013145. https:\/\/doi.org\/10.1056\/NEJMoa022328","journal-title":"N Engl J Med"},{"key":"4828_CR27","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1191\/135245801681137979","volume":"7","author":"R Egg","year":"2001","unstructured":"Egg R, Reindl M, Deisenhammer F, Linington C, Berger T (2001) Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis. Mult Scler 7:285\u2013289. https:\/\/doi.org\/10.1191\/135245801681137979","journal-title":"Mult Scler"},{"key":"4828_CR28","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.clim.2010.11.013","volume":"138","author":"F Di Pauli","year":"2011","unstructured":"Di Pauli F, Mader S, Rostasy K, Schanda K, Bajer-Kornek B, Ehling R et al (2011) Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. Clin Immunol 138:247\u2013254. https:\/\/doi.org\/10.1016\/j.clim.2010.11.013","journal-title":"Clin Immunol"},{"key":"4828_CR29","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/ana.21916","volume":"66","author":"F Brilot","year":"2009","unstructured":"Brilot F, Dale RC, Selter RC, Grummel V, Kalluri SR, Aslam M et al (2009) Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol 66:833\u2013842. https:\/\/doi.org\/10.1002\/ana.21916","journal-title":"Ann Neurol"},{"key":"4828_CR30","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1177\/1352458510389220","volume":"17","author":"PH Lalive","year":"2011","unstructured":"Lalive PH, H\u00e4usler MG, Maurey H, Mikaeloff Y, Tardieu M, Wiendl H, Schroeter M, Hartung HP, Kieseier BC, Menge T (2011) Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children. Mult Scler J 17:297\u2013302. https:\/\/doi.org\/10.1177\/1352458510389220","journal-title":"Mult Scler J"},{"key":"4828_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1742-2094-8-184","volume":"8","author":"S Mader","year":"2011","unstructured":"Mader S, Gredler V, Schanda K, Rostasy K, Dujmovic I, Pfaller K, Lutterotti A, Jarius S, di Pauli F, Kuenz B, Ehling R, Hegen H, Deisenhammer F, Aboul-Enein F, Storch MK, Koson P, Drulovic J, Kristoferitsch W, Berger T, Reindl M (2011) Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation 8:1\u201314. https:\/\/doi.org\/10.1186\/1742-2094-8-184","journal-title":"J Neuroinflammation"},{"key":"4828_CR32","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1177\/1352458512470310","volume":"19","author":"K Rost\u00e1sy","year":"2013","unstructured":"Rost\u00e1sy K, Mader S, Hennes EM, Schanda K, Gredler V, Guenther A, Blaschek A, Korenke C, Pritsch M, Pohl D, Maier O, Kuchukhidze G, Brunner-Krainz M, Berger T, Reindl M (2013) Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. Mult Scler J 19:1052\u20131059. https:\/\/doi.org\/10.1177\/1352458512470310","journal-title":"Mult Scler J"},{"key":"4828_CR33","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","volume":"79","author":"J Kitley","year":"2012","unstructured":"Kitley J, Woodhall M, Waters P, Leite MI, Devenney E, Craig J, Palace J, Vincent A (2012) Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology. 79:1273\u20131277. https:\/\/doi.org\/10.1212\/WNL.0b013e31826aac4e","journal-title":"Neurology."},{"key":"4828_CR34","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1001\/archneurol.2011.2956","volume":"69","author":"K Rostasy","year":"2012","unstructured":"Rostasy K, Mader S, Schanda K, Huppke P, G\u00e4rtner J, Kraus V, Karenfort M, Tibussek D, Blaschek A, Bajer-Kornek B, Leitz S, Schimmel M, di Pauli F, Berger T, Reindl M (2012) Anti\u2013myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis. Arch Neurol 69:752\u2013756. https:\/\/doi.org\/10.1001\/archneurol.2011.2956","journal-title":"Arch Neurol"},{"key":"4828_CR35","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1177\/1352458518811597","volume":"25","author":"LM Oliveira","year":"2018","unstructured":"Oliveira LM, Ap\u00f3stolos-Pereira SL, Pitombeira MS, Bruel Torretta PH, Callegaro D, Sato DK (2018) Persistent MOG-IgG positivity is a predictor of recurrence in MOG-IgG-associated optic neuritis, encephalitis and myelitis. Mult Scler J 25:1907\u20131914. https:\/\/doi.org\/10.1177\/1352458518811597","journal-title":"Mult Scler J"},{"key":"4828_CR36","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1093\/brain\/awx276","volume":"140","author":"M Jurynczyk","year":"2017","unstructured":"Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, Roca-Fernandez A, Tackley G, Hamid S, Sheard A, Reynolds G, Chandratre S, Hemingway C, Jacob A, Vincent A, Leite MI, Waters P, Palace J (2017) Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 140:3128\u20133138. https:\/\/doi.org\/10.1093\/brain\/awx276","journal-title":"Brain."},{"key":"4828_CR37","doi-asserted-by":"publisher","first-page":"e1858","DOI":"10.1212\/wnl.0000000000005560","volume":"90","author":"A Cobo-Calvo","year":"2018","unstructured":"Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, Ciron J, Collongues N, Brassat D, Cotton F, Papeix C, Durand-Dubief F, Laplaud D, Deschamps R, Cohen M, Biotti D, Ayrignac X, Tilikete C, Thouvenot E, Brochet B, Dulau C, Moreau T, Tourbah A, Lebranchu P, Michel L, Lebrun-Frenay C, Montcuquet A, Mathey G, Debouverie M, Pelletier J, Labauge P, Derache N, Coustans M, Rollot F, de Seze J, Vukusic S, Marignier R, OFSEP and NOMADMUS Study Group (2018) Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults. Neurology. 90:e1858\u2013e1869. https:\/\/doi.org\/10.1212\/wnl.0000000000005560","journal-title":"Neurology."},{"key":"4828_CR38","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1212\/WNL.0b013e318228c0b1","volume":"77","author":"AK Pr\u00f6bstel","year":"2011","unstructured":"Pr\u00f6bstel AK, Dornmair K, Bittner R, Sperl P, Jenne D, Magalhaes S et al (2011) Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology. 77:580\u2013588. https:\/\/doi.org\/10.1212\/WNL.0b013e318228c0b1","journal-title":"Neurology."},{"key":"4828_CR39","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1111\/dmcn.13703","volume":"60","author":"S Duignan","year":"2018","unstructured":"Duignan S, Wright S, Rossor T, Cazabon J, Gilmour K, Ciccarelli O, Wassmer E, Lim M, Hemingway C, Hacohen Y (2018) Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes. Dev Med Child Neurol 60:958\u2013962. https:\/\/doi.org\/10.1111\/dmcn.13703","journal-title":"Dev Med Child Neurol"},{"key":"4828_CR40","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/S0165-5728(00)00462-8","volume":"114","author":"CG Haase","year":"2001","unstructured":"Haase CG, Guggenmos J, Brehm U, Andersson M, Olsson T, Reindl M, Schneidewind JM, Zettl UK, Heidenreich F, Berger T, Wekerle H, Hohlfeld R, Linington C (2001) The fine specificity of the myelin oligodendrocyte glycoprotein autoantibody response in patients with multiple sclerosis and normal healthy controls. J Neuroimmunol 114:220\u2013225. https:\/\/doi.org\/10.1016\/S0165-5728(00)00462-8","journal-title":"J Neuroimmunol"},{"key":"4828_CR41","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/1352458506072189","volume":"13","author":"SJ Pittock","year":"2007","unstructured":"Pittock SJ, Reindl M, Achenbach S, Berger T, Bruck W, Konig F, Morales Y, Lassmann H, Bryant S, Moore SB, Keegan BM, Lucchinetti CF (2007) Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: frequency, stability and clinicopathologic correlations. Mult Scler 13:7\u201316. https:\/\/doi.org\/10.1177\/1352458506072189","journal-title":"Mult Scler"},{"key":"4828_CR42","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMc062467","volume":"356","author":"R Pelayo","year":"2007","unstructured":"Pelayo R, Tintor\u00e9 M, Montalban X, Rovira A, Espejo C, Reindl M, Berger T (2007) Antimyelin antibodies with no progression to multiple sclerosis. N Engl J Med 356:426\u2013428. https:\/\/doi.org\/10.1056\/NEJMc062467","journal-title":"N Engl J Med"},{"key":"4828_CR43","doi-asserted-by":"publisher","first-page":"e1250","DOI":"10.1212\/WNL.0000000000007096","volume":"92","author":"PJ Waters","year":"2019","unstructured":"Waters PJ, Komorowski L, Woodhall M, Lederer S, Majed M, Fryer J, Mills J, Flanagan EP, Irani SR, Kunchok AC, McKeon A, Pittock SJ (2019) A multicenter comparison of MOG-IgG cell-based assays. Neurology. 92:e1250\u2013e1255. https:\/\/doi.org\/10.1212\/WNL.0000000000007096","journal-title":"Neurology."},{"key":"4828_CR44","doi-asserted-by":"publisher","first-page":"950","DOI":"10.3892\/etm.2018.6273","volume":"16","author":"Y Peng","year":"2018","unstructured":"Peng Y, Liu L, Zheng Y, Qiao Z, Feng K, Wang J (2018) Diagnostic implications of MOG\/AQP4 antibodies in recurrent optic neuritis. Exp Ther Med 16:950\u2013958. https:\/\/doi.org\/10.3892\/etm.2018.6273","journal-title":"Exp Ther Med"},{"key":"4828_CR45","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2144\/000113132","volume":"47","author":"LB Jacobsen","year":"2009","unstructured":"Jacobsen LB, Calvin SA, Lobenhofer EK (2009) Transcriptional effects of transfection: the potential for misinterpretation of gene expression data generated from transiently transfected cells. Biotechniques. 47:617\u2013624. https:\/\/doi.org\/10.2144\/000113132","journal-title":"Biotechniques."},{"key":"4828_CR46","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1055\/s-0037-1604404","volume":"49","author":"E-M Hennes","year":"2018","unstructured":"Hennes E-M, Baumann M, Lechner C, Rost\u00e1sy K (2018) MOG Spectrum disorders and role of MOG-antibodies in clinical practice. Neuropediatrics. 49:3\u201311. https:\/\/doi.org\/10.1055\/s-0037-1604404","journal-title":"Neuropediatrics."},{"key":"4828_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/NXI.0000000000000089","volume":"2","author":"P Waters","year":"2015","unstructured":"Waters P, Woodhall M, O\u2019Connor KC, Reindl M, Lang B, Sato DK et al (2015) MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol NeuroInflammation. 2:1\u201311. https:\/\/doi.org\/10.1212\/NXI.0000000000000089","journal-title":"Neurol Neuroimmunol NeuroInflammation."},{"key":"4828_CR48","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/0014-5793(96)00586-8","volume":"389","author":"H-H Gerdes","year":"1996","unstructured":"Gerdes H-H, Kaether C (1996) Green fluorescent protein: applications in cell biology. FEBS Lett 389:44\u201347. https:\/\/doi.org\/10.1016\/0014-5793(96)00586-8","journal-title":"FEBS Lett"},{"key":"4828_CR49","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/S0168-9525(00)89092-7","volume":"11","author":"J Pines","year":"1995","unstructured":"Pines J (1995) GFP in mammalian cells. Trends Genet 11:326\u2013327. https:\/\/doi.org\/10.1016\/S0168-9525(00)89092-7","journal-title":"Trends Genet"},{"key":"4828_CR50","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/B978-0-12-386932-6.00008-9","volume":"113","author":"Y Ohba","year":"2013","unstructured":"Ohba Y, Fujioka Y, Nakada S, Tsuda M (2013) Fluorescent protein-based biosensors and their clinical applications. Prog Mol Biol Transl Sci 113:313\u2013348. https:\/\/doi.org\/10.1016\/B978-0-12-386932-6.00008-9","journal-title":"Prog Mol Biol Transl Sci"},{"key":"4828_CR51","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1006\/BBRC.1999.0954","volume":"260","author":"H-S Liu","year":"1999","unstructured":"Liu H-S, Jan M-S, Chou C-K, Chen P-H, Ke N-J (1999) Is green fluorescent protein toxic to the living cells? Biochem Biophys Res Commun 260:712\u2013717. https:\/\/doi.org\/10.1006\/BBRC.1999.0954","journal-title":"Biochem Biophys Res Commun"},{"key":"4828_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0010455","volume":"5","author":"S Mader","year":"2010","unstructured":"Mader S, Lutterotti A, Di Pauli F, Kuenz B, Schanda K, Aboul-Enein F et al (2010) Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica. PLoS One 5:1\u20137. https:\/\/doi.org\/10.1371\/journal.pone.0010455","journal-title":"PLoS One"},{"key":"4828_CR53","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1007\/s10895-017-2109-z","volume":"27","author":"AK Dash","year":"2017","unstructured":"Dash AK, Yende AS, Tyagi RK (2017) Novel application of red fluorescent protein (DsRed-express) for the study of functional dynamics of nuclear receptors. J Fluoresc 27:1225\u20131231. https:\/\/doi.org\/10.1007\/s10895-017-2109-z","journal-title":"J Fluoresc"},{"key":"4828_CR54","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/cen3.12107","volume":"5","author":"PJ Waters","year":"2014","unstructured":"Waters PJ, Pittock SJ, Bennett JL, Jarius S, Weinshenker BG, Wingerchuk DM (2014) Evaluation of aquaporin-4 antibody assays. Clin Exp Neuroimmunol 5:290\u2013303. https:\/\/doi.org\/10.1111\/cen3.12107","journal-title":"Clin Exp Neuroimmunol"},{"key":"4828_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-019-1525-1","volume":"16","author":"A Cobo-Calvo","year":"2019","unstructured":"Cobo-Calvo A, Sep\u00falveda M, Rollot F, Armangu\u00e9 T, Ruiz A, Maillart E, Papeix C, Audoin B, Zephir H, Biotti D, Ciron J, Durand-Dubief F, Collongues N, Ayrignac X, Labauge P, Thouvenot E, Bourre B, Montcuquet A, Cohen M, Deschamps R, Sol\u00e0-Valls N, Llufriu S, de Seze J, Blanco Y, Vukusic S, Saiz A, Marignier R (2019) Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. J Neuroinflammation 16:1\u201312. https:\/\/doi.org\/10.1186\/s12974-019-1525-1","journal-title":"J Neuroinflammation"},{"key":"4828_CR56","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.msard.2019.01.007","volume":"28","author":"M Pedre\u00f1o","year":"2019","unstructured":"Pedre\u00f1o M, Sep\u00falveda M, Armangu\u00e9 T, Sabater L, Mart\u00ednez-Hernandez E, Arrambide G, Blanco Y, Llufriu S, Mart\u00ednez-Lapiscina EH, Mulero P, Sola-Valls N, Ruiz-Garc\u00eda R, Tintor\u00e9 M, Dalmau J, Graus F, Saiz A (2019) Frequency and relevance of IgM, and IgA antibodies against MOG in MOG-IgG-associated disease. Mult Scler Relat Disord. 28:230\u2013234. https:\/\/doi.org\/10.1016\/j.msard.2019.01.007","journal-title":"Mult Scler Relat Disord."},{"key":"4828_CR57","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1007\/s00415-017-8635-4","volume":"264","author":"S Mariotto","year":"2017","unstructured":"Mariotto S, Ferrari S, Monaco S, Benedetti MD, Schanda K, Alberti D, Farinazzo A, Capra R, Mancinelli C, de Rossi N, Bombardi R, Zuliani L, Zoccarato M, Tanel R, Bonora A, Turatti M, Calabrese M, Polo A, Pavone A, Grazian L, Sechi GP, Sechi E, Urso D, Delogu R, Janes F, Deotto L, Cadaldini M, Bianchi MR, Cantalupo G, Reindl M, Gajofatto A (2017) Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study. J Neurol 264:2420\u20132430. https:\/\/doi.org\/10.1007\/s00415-017-8635-4","journal-title":"J Neurol"},{"key":"4828_CR58","doi-asserted-by":"publisher","unstructured":"Gastaldi M, Scaranzin S, Jarius S, Wildeman B, Zardini E, Mallucci G, Rigoni E, Vegezzi E, Foiadelli T, Savasta S, Banfi P, Versino M, Benedetti L, Novi G, Mancardi MM, Giacomini T, Annovazzi P, Baroncini D, Ferraro D, Lampasona V, Reindl M, Waters P, Franciotta D (2020) Cell-based assays for the detection of MOG antibodies: a comparative study. J Neurol:1\u201310. https:\/\/doi.org\/10.1007\/s00415-020-10024-0","DOI":"10.1007\/s00415-020-10024-0"},{"key":"4828_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.msard.2020.101939","volume":"40","author":"Y Kim","year":"2020","unstructured":"Kim Y, Hyun J-W, Woodhall MR, Oh Y-M, Lee J-E, Jung JY, Kim SY, Lee MY, Kim SH, Kim W, Irani SR, Waters P, Choi K, Kim HJ (2020) Refining cell-based assay to detect MOG-IgG in patients with central nervous system inflammatory diseases. Mult Scler Relat Disord. 40:1\u20139. https:\/\/doi.org\/10.1016\/j.msard.2020.101939","journal-title":"Mult Scler Relat Disord."},{"key":"4828_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jneuroim.2019.577021","volume":"336","author":"K Sugimoto","year":"2019","unstructured":"Sugimoto K, Mori M, Liu J, Tanaka S, Kaneko K, Oji S, Takahashi T, Uzawa A, Uchida T, Masuda H, Ohtani R, Nomura K, Hiwasa T, Kuwabara S (2019) The accuracy of flow cytometric cell-based assay to detect anti-myelin oligodendrocyte glycoprotein (MOG) antibodies determining the optimal method for positivity judgement. J Neuroimmunol 336:1\u20139. https:\/\/doi.org\/10.1016\/j.jneuroim.2019.577021","journal-title":"J Neuroimmunol"},{"key":"4828_CR61","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1136\/jnnp-2015-312601","volume":"87","author":"P Waters","year":"2016","unstructured":"Waters P, Reindl M, Saiz A, Schanda K, Tuller F, Kral V, Nytrova P, Sobek O, Nielsen HH, Barington T, Lillevang ST, Illes Z, Rentzsch K, Berthele A, Berki T, Granieri L, Bertolotto A, Giometto B, Zuliani L, Hamann D, van Pelt ED, Hintzen R, H\u00f6ftberger R, Costa C, Comabella M, Montalban X, Tintor\u00e9 M, Siva A, Altintas A, Deniz G, Woodhall M, Palace J, Paul F, Hartung HP, Aktas O, Jarius S, Wildemann B, Vedeler C, Ruiz A, Leite MI, Trillenberg P, Probst M, Saschenbrecker S, Vincent A, Marignier R (2016) Multicentre comparison of a diagnostic assay: Aquaporin-4 antibodies in neuromyelitis optica. J Neurol Neurosurg Psychiatry 87:1005\u20131015. https:\/\/doi.org\/10.1136\/jnnp-2015-312601","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"4828_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/nxi.0000000000000674","volume":"7","author":"M Reindl","year":"2020","unstructured":"Reindl M, Schanda K, Woodhall M, Tea F, Ramanathan S, Sagen J, Fryer JP, Mills J, Teegen B, Mindorf S, Ritter N, Krummrei U, St\u00f6cker W, Eggert J, Flanagan EP, Ramberger M, Hegen H, Rostasy K, Berger T, Leite MI, Palace J, Irani SR, Dale RC, Probst C, Probst M, Brilot F, Pittock SJ, Waters P (2020) An international multicenter examination of MOG antibody assays. Neuroimmunol Neuroinfllammation 7:1\u201312. https:\/\/doi.org\/10.1212\/nxi.0000000000000674","journal-title":"Neuroimmunol Neuroinfllammation"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-020-04828-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-020-04828-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-020-04828-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T05:39:11Z","timestamp":1634276351000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-020-04828-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["4828"],"URL":"https:\/\/doi.org\/10.1007\/s10072-020-04828-1","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,15]]},"assertion":[{"value":"18 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that this research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.AM has received a scholarship from CAPES\/Brazil.MW has no disclosures.PW and the University of Oxford hold patents and receive royalties for antibody assays. PW has received honoraria from Alexion and UBC and a research grant from Euroimmun AG.DKS has received a scholarship from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan; a Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (KAKENHI 15K19472); research support from CNPq\/Brazil (425331\/2016-4), FAPERGS\/MS\/CNPq\/SESRS (17\/2551-0001391-3) PPSUS\/Brazil, TEVA (research grant for EMOCEMP Investigator Initiated Study), and Euroimmun AG (Neuroimmunological Complications associated with Arboviruses); and speaker honoraria from Biogen, Novartis, Genzyme, TEVA, Merck Serono, Roche, and Bayer and has participated in advisory boards for Shire, Roche, TEVA, Merck Serono, and Quest\/Athena Diagnostics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"\u00a0Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}